Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Crashing Today

By George Budwell – Sep 8, 2020 at 11:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst downgrade is crushing the biotech's stock today.

What happened

Shares of vaccine specialist Moderna (MRNA 3.17%) are under enormous pressure Tuesday morning following a sizable downgrade from SVB Leerink. Citing competitive pressures in the COVID-19 vaccine space, the investment firm lowered its 12-month price target on Moderna's shares to $41 from $58.

Basically, Leerink is calling for Moderna's shares to fall by a hefty 34% compared with where they closed last Friday. In response, the biotech's stock is off by a noteworthy 11.4% as of 9:47 a.m. EDT Tuesday. 

A scientist holding a vial labeled COVID-19 Vaccine

Image source: Getty Images.

So what

Although Moderna was the first company to enter human trials with its COVID-19 vaccine candidate known as mRNA-1273, AstraZeneca and Pfizer appear to have overtaken their smaller peer from a development standpoint. Pfizer, in fact, might have its COVID-19 vaccine on the market through an emergency use authorization by Halloween. And AstraZeneca probably won't be far behind.

Moderna, by contrast, is expected to have its vaccine ready for widespread public use toward the end of the year. If this timeline holds up, Moderna may end up losing a sizable chunk of market share to its chief competitors. 

Now what

Is this analyst downgrade overly pessimistic? Unfortunately for shareholders, the answer is probably a no. Moderna doesn't have any approved products to fall back on in case it can't beat either AstraZeneca or Pfizer to market, and these two big pharmas have the commercial infrastructure in place to gobble up market share in a hurry. In short, this clinical-stage biotech stock has probably already seen its high-water mark from the COVID-19 vaccine race.  

George Budwell owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Moderna Stock Quote
Moderna
MRNA
$181.48 (3.17%) $5.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.